Status: Recruiting
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with refractory autoimmune diseases, including active systemic lupus erythematosus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM).
Participants needed: 80
Trial details
Phase: Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: CRISPR TherapeuticsUpdated: Jun 15, 2026Locations: 14
Eligibility criteria
Age ≥18 years and < 70 years of age. [+5]
Prior anti-CD19 therapy or any gene therapy/genetically modified cell therapy. [+12]